Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease

Summary

Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease is a clinical trial^[1].

Key Facts

• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease is in the country of France^[2].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's instance of is recorded as clinical trial^[3].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's start time is recorded as +2013-01-14T00:00:00Z^[4].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's end time is recorded as +2018-04-30T00:00:00Z^[5].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's sponsor is recorded as Assistance Publique – Hôpitaux de Paris^[6].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's main subject is recorded as sclerosis^[7].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's main subject is recorded as pulmonary fibrosis^[8].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's number of participants is recorded as {'unit': '1', 'amount': '+40'}^[9].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's title is recorded as Intravenous Cyclophosphamide for the Treatment of Systemic Sclerosis Associated Interstitial Lung Disease^[10].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's short name is recorded as SCLEROCYC^[11].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[12].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's ClinicalTrials.gov ID is recorded as NCT01570764^[13].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's research intervention is recorded as (RS)-cyclophosphamide^[14].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's research intervention is recorded as prednisone^[15].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's clinical trial phase is recorded as phase III clinical trial^[16].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's research site is recorded as Cochin hospital chapel^[17].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's research subject recruitment status is recorded as completed^[18].
• Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease's study type is recorded as interventional study^[19].